Abstract: The present invention relates to the technical field of medicines. Specifically disclosed is a compound as represented by formula I?, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, symbols therein being as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has good pharmacokinetic properties.
Abstract: A kinase inhibitor compound of formula I or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The compound has good inhibitory activity on EGFR and Her2 exon 20 insertion mutation, EGFR exon 19 deletion and L858R point mutation of exon 21.
Type:
Application
Filed:
March 15, 2021
Publication date:
May 18, 2023
Applicants:
TYK MEDICINES (ZHENGZHOU), INC., TYK MEDICINES, INC.
Abstract: The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmacodynamic and pharmacokinetic performance, and lower toxic side effects.
Abstract: The present invention relates to a compound used as a kinase inhibitor and to the use thereof. The structure of the compound is as shown in formula I. The present compound used as a kinase inhibitor has good inhibitory activity on EGFR and Her2 exon 20 insertion mutations, and has excellent potential to be developed into a drug for treating related diseases.
Type:
Application
Filed:
April 16, 2021
Publication date:
March 23, 2023
Applicants:
TYK MEDICINES (ZHENGZHOU), INC., TYK MEDICINES, INC.
Inventors:
Jun LI, Apeng LIANG, Chengshan NIU, Yusheng WU
Abstract: The present invention relates to a compound used as an EGFR kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, and can be used to adjust the kinase activity or treat related diseases, especially non-small cell lung cancer.
Abstract: The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I?), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol therein is as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has better pharmacokinetic properties.
Abstract: A crystal form of a deuterated AZD9291 has an X-ray powder diffraction measured using Cu-K? rays with diffraction peaks at 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2. The crystal form of the deuterated AZD9291 is used in the preparation of medicaments for the treatment of cancer. The crystal form of the deuterated AZD9291 provided by the present invention has stable physical and chemical properties and good metabolic stability, and blood concentrations in vivo and concentrations in the brain thereof are significantly improved, achieving an improved therapeutic effect.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
January 5, 2021
Assignee:
TYK MEDICINES INC.
Inventors:
Yusheng Wu, Yang Geng, Apeng Liang, Chengshan Niu